Kallistatin inhibits TGF-β-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression

Experimental Cell Research

Volumn 337, Issue 1, 2015, Pages 103-110

  Guo, Youming ^a   Li, Pengfei ^a   Bledsoe, Grant ^a   Yang, Zhi Rong ^a   Chao, Lee ^a   Chao, Julie ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

EndMT; ENOS; Kallistatin; MiR 21; Oxidative stress; TGF

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KALLISTATIN; MICRORNA 21; PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIRTUIN 1; SNAIL1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; MICRORNA; MIRN21 MICRORNA, HUMAN; NOS3 PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BINDING SITE; CELL TRANSFORMATION; CONTROLLED STUDY; ENDOTHELIAL MESENCHYMAL TRANSITION; ENDOTHELIUM CELL; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; ENZYME ACTIVE SITE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY;

ANIMALIA;

CATALYTIC DOMAIN; ENDOTHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEK293 CELLS; HUMANS; MICRORNAS; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; REACTIVE OXYGEN SPECIES; SERPINS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84939575336     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.06.021     Document Type: Article

References (45)

1. Lin F., Wang N., Zhang T.C. The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life 2012, 64:717-723.
2. Braitsch C.M., Kanisicak O., van Berlo J.H., Molkentin J.D., Yutzey K.E. Differential expression of embryonic epicardial progenitor markers and localization of cardiac fibrosis in adult ischemic injury and hypertensive heart disease. J. Mol. Cell. Cardiol. 2013, 65:108-119.
3. Zeisberg E.M., Potenta S.E., Sugimoto H., Zeisberg M., Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 2008, 19:2282-2287.
4. Hashimoto N., Phan S.H., Imaizumi K., Matsuo M., Nakashima H., Kawabe T., Shimokata K., Hasegawa Y. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2010, 43:161-172.
5. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 2003, 112:1776-1784.
6. Yoshimatsu Y., Watabe T. Roles of TGF-beta signals in endothelial-mesenchymal transition during cardiac fibrosis. Int. J. Inflam. 2011, 2011:724080.
7. van Meeteren L.A., ten Dijke P. Regulation of endothelial cell plasticity by TGF-beta. Cell Tissue Res. 2012, 347:177-186.
8. Peinado H., Quintanilla M., Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J. Biol. Chem. 2003, 278:21113-21123.
9. Huber M.A., Azoitei N., Baumann B., Grunert S., Sommer A., Pehamberger H., Kraut N., Beug H., Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 2004, 114:569-581.
10. Meadows K.N., Iyer S., Stevens M.V., Wang D., Shechter S., Perruzzi C., Camenisch T.D., Benjamin L.E. Akt promotes endocardial-mesenchyme transition. J. Angiogenesis Res. 2009, 1:2.
11. Julien S., Puig I., Caretti E., Bonaventure J., Nelles L., van Roy F., Dargemont C., de Herreros A.G., Bellacosa A., Larue L. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007, 26:7445-7456.
12. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., Galuppo P., Just S., Rottbauer W., Frantz S., Castoldi M., Soutschek J., Koteliansky V., Rosenwald A., Basson M.A., Licht J.D., Pena J.T., Rouhanifard S.H., Muckenthaler M.U., Tuschl T., Martin G.R., Bauersachs J., Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
13. Luo F., Ji J., Liu Y., Xu Y., Zheng G., Jing J., Wang B., Xu W., Shi L., Lu X., Liu Q. MicroRNA-21, up-regulated by arsenite, directs the epithelial-mesenchymal transition and enhances the invasive potential of transformed human bronchial epithelial cells by targeting PDCD4. Toxicol. Lett. 2014, 232:301-309.
14. Kumarswamy R., Volkmann I., Jazbutyte V., Dangwal S., Park D.H., Thum T. Transforming growth factor-beta-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler. Thromb. Vasc. Biol. 2012, 32:361-369.
15. Chao J., Chao L. Biochemistry, regulation and potential function of kallistatin. Biol. Chem. Hoppe Seyler 1995, 376:705-713.
16. Ling M., Li Y., Xu Y., Pang Y., Shen L., Jiang R., Zhao Y., Yang X., Zhang J., Zhou J., Wang X., Liu Q. Regulation of miRNA-21 by reactive oxygen species-activated ERK/NF-kappaB in arsenite-induced cell transformation. Free Radic. Biol. Med. 2012, 52:1508-1518.
17. Chen L.M., Song Q., Chao L., Chao J. Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int. 1995, 48:690-697.
18. Wolf W.C., Harley R.A., Sluce D., Chao L., Chao J. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J. Histochem. Cytochem. 1999, 47:221-228.
19. Chen V.C., Chao L., Chao J. A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. J. Biol. Chem. 2000, 275:40371-40377.
20. Chen V.C., Chao L., Pimenta D.C., Bledsoe G., Juliano L., Chao J. Identification of a major heparin-binding site in kallistatin. J. Biol. Chem. 2001, 276:1276-1284.
21. Miao R.Q., Chen V., Chao L., Chao J. Structural elements of kallistatin required for inhibition of angiogenesis. Am. J. Physiol. Cell Physiol. 2003, 284:C1604-C1613.
22. Yin H., Gao L., Shen B., Chao L., Chao J. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension 2010, 56:260-267.
23. Li P., Bledsoe G., Yang Z.R., Fan H., Chao L., Chao J. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology 2014, 142:216-226.
24. Chao J., Yin H., Yao Y.Y., Shen B., Smith R.S., Chao L. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum. Gene Ther. 2006, 17:1201-1213.
25. Shen B., Hagiwara M., Yao Y.Y., Chao L., Chao J. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 2008, 51:1358-1365.
26. Shen B., Gao L., Hsu Y.T., Bledsoe G., Hagiwara M., Chao L., Chao J. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H1419-H1427.
27. Miao R.Q., Agata J., Chao L., Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002, 100:3245-3252.
28. Gao L., Yin H., Smith R J.S., Chao L., Chao J. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest. 2008, 88:1157-1166.
29. Huang X., Wang X., Lv Y., Xu L., Lin J., Diao Y. Protection effect of kallistatin on carbon tetrachloride-induced liver fibrosis in rats via antioxidative stress. PLoS One 2014, 9:e88498.
30. Chen V.C., Chao L., Chao J. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim. Biophys. Acta 2000, 1479:237-246.
31. Chao J., Schmaier A., Chen L.M., Yang Z., Chao L. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J. Lab. Clin. Med. 1996, 127:612-620.
32. Ding G., Zhang A., Huang S., Pan X., Zhen G., Chen R., Yang T. ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR. Am. J. Physiol. Renal Physiol. 2007, 293:F1889-F1897.
33. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994, 74:1141-1148.
34. Yan F., Wang Y., Wu X., Peshavariya H.M., Dusting G.J., Zhang M., Jiang F. Nox4 and redox signaling mediate TGF-beta-induced endothelial cell apoptosis and phenotypic switch. Cell Death Dis. 2014, 5:e1010.
35. Clancy R.M., Leszczynska-Piziak J., Abramson S.B. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J. Clin. Invest. 1992, 90:1116-1121.
36. Kumarswamy R., Volkmann I., Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. 2011, 8:706-713.
37. Turner N.A., Porter K.E. Function and fate of myofibroblasts after myocardial infarction. Fibrogenesis Tissue Repair 2013, 6:5.
38. Jiang Y., Chen X., Tian W., Yin X., Wang J., Yang H. The role of TGF-beta1-miR-21-ROS pathway in bystander responses induced by irradiated non-small-cell lung cancer cells. Br. J. Cancer 2014, 111:772-780.
39. Yan C., Boyd D.D. Regulation of matrix metalloproteinase gene expression. J. Cell. Physiol. 2007, 211:19-26.
40. Potenta S., Zeisberg E., Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br. J. Cancer 2008, 99:1375-1379.
41. Chao J., Chai K.X., Chen L.M., Xiong W., Chao S., Woodley-Miller C., Wang L.X., Lu H.S., Chao L. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J. Biol. Chem. 1990, 265:16394-16401.
42. Adhikari N., Basi D.L., Townsend D., Rusch M., Mariash A., Mullegama S., Watson A., Larson J., Tan S., Lerman B., Esko J.D., Selleck S.B., Hall J.L. Heparan sulfate Ndst1 regulates vascular smooth muscle cell proliferation, vessel size and vascular remodeling. J. Mol. Cell. Cardiol. 2010, 49:287-293.
43. Sarrazin S., Lamanna W.C., Esko J.D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 2011, 3:a004952.
44. Fujii H., Ichimori K., Hoshiai K., Nakazawa H. Nitric oxide inactivates NADPH oxidase in pig neutrophils by inhibiting its assembling process. J. Biol. Chem. 1997, 272:32773-32778.
45. Storz P. Forkhead homeobox type O transcription factors in the responses to oxidative stress. Antioxid. Redox Signal. 2011, 14:593-605.